Abstract:Background: After decades of use, clinicians and medical societies are still debating on the clinical utility of mammography, the standard of care for breast cancer (BC) screening, because of its limitations such as subjective visual interpretation, high rate of false-positive and false-negative (in dense breast) and concerns over radiation exposure. There are 55 million women, and about 45% of them considered dense breast, in need of an accurate, easy to use test for the screening of BC regardless of breast tissue complexities to differentiate between BC and benign findings such as calcification and fibrosis. To this date there is no blood protein biomarker (BM) in clinical use for the early detection of BC. We have developed a novel BC specific protein biomarker -based blood test to detect patients with early-stage BC and established herein the diagnostic performance of our BM in discriminating BC patients from healthy individuals and benign breast cases. Methods: A total of 433 serum samples (318 primary BC, 32 benign breast and 83 normal breast) were obtained from the Cooperative Human Tissue Network and from the IRCCS San Raffaele Pisana Research Center (blind samples). 247 BC samples were provided as blind samples and were used to validate the screening utility. Serum samples were tested with our BC specific BM by sandwich ELISA. Receiver operating characteristic (ROC) curves were calculated to evaluate the diagnostic performance, by determining sensitivity (SE), specificity (SP), area under the curve (AUC), and confidence interval (CI). Statistical analysis, ROC curves and scatter plots were performed with GraphPad Prism 7.0. Results: BM elevation in early cancer cases (stage I-II, Ductal Carcinoma) was found to be statistically significant (p< 0.0001) as compared to healthy and benign cases. Our test discriminated early BC patients from non-cancer cases with 87.3% SE at 85.2% SP and was further validated in a blind set including 247 BC (Ductal & Lobular Carcinoma, stage I-III), 30 benign and 83 normal breast cases (88%SE, 86%SP). The sensitivity for early-stage (I-II) and late stage (III) BC was 86.8% and 94.3%, respectively. While lobular carcinoma is particularly not well detected by mammography with a sensitivity as low as 57% and much lower for women with dense breast, it was detected with high sensitivity (90%) in our test. 80% of fibrocystic changes (FCC), the most common form of benign breast disease in women over 50 years of age were negative with our test. Although it is a benign condition, FCC may be misdiagnosed as a malignant lesion by physical examination and imaging. Conclusion: Our results support the utility of our blood-based test for the early detection of breast cancer which presents improved features over mammography such as higher lobular cancer sensitivity, lower detection rate of common form of benign condition often misdiagnosed by imaging, absence of radiation and expected high compliance. Further testing is needed to confirm accuracy of our test in the dense breast population. Citation Format: Christine Chavany, Jeffrey Dea, Monica Guevara, Rafael Hernandez-Gonzalez, Patrizia Ferroni, Fiorella Guadagni, Rosaura Valle, Moncef Jendoubi. A Serum Biomarker for the Early Detection of Breast cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl) nr PO5-07-08.

Novel Noninvasive Serum Biomarkers for Prompt Diagnosis of Breast Carcinoma

Largescale Multicenter Study of a Serum Metabolite Biomarker Panel for the Diagnosis of Breast Cancer

The Role of Tumor Markers: Carcinoembryonic Antigen and Cancer Antigen 15-3 in Patients With Breast Cancer

Impending role of inflammatory markers and their specificity and sensitivity in breast cancer patients

Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples

Association of Proliferative Activity in Invasive Ductal Carcinoma Breast in Pakistani Population

Dual-function Biomarkers for Detection of Breast Cancer and Its Cancer Type: Invasive Versus Non-Invasive.

[Analysis of Serum Metabonome of Patients with Breast Cancer by Gas Chromatography-Mass Spectrometry].

Detection and identification of potential biomarkers of breast cancer

The role of biomarkers in diagnosing breast cancer: a review

A serum glycomics approach to breast cancer biomarkers

Developing a Novel Non-invasive Serum-based Diagnostic Test for Early Detection of Colorectal Cancer

Abstract PO5-07-08: A Serum Biomarker for the Early Detection of Breast cancer

Detection and Identification of Serum Protein Peak at 6648 M/z As a Novel Indicator in Breast Cancer Based on Mass Spectrometry.

Innovation in Breast Cancer Treatment and it’s Potential in Pakistan

Combining nuclear matrix protein-52, collagen III, and matrix metalloproteinase-1 for more effective breast cancer early detection

Serum semaphorin 4C as a diagnostic biomarker in breast cancer: A multicenter retrospective study

Diagnostic Accuracy of Cancer Antigen 15-3 as a Seromarker Among Recurrent Breast Carcinoma in Bangladesh

Primary breast cancer biomarkers based on glycosylation and extracellular vesicles detected from human serum

Current Situation of Breast Cancer in Pakistan and the Dire Need of Early Diagnosis

Non-Invasive Biomarkers for Early Detection of Breast Cancer